Melbourne Infant Study - Bacille Calmette Guérin (BCG) for Allergy & Infection Reduction

Exclusion Criteria

• •Any indication for BCG immunisation in the first 12 months of life including:
• •* likely travel to a high tuberculosis (TB) incidence country in the first year of life.
• •* Aboriginal and Torres Strait Islander babies living in parts of Australia where the incidence of TB is higher
• •* newborn babies, if either parent has leprosy or a family history of leprosy
• •* newborn in contact with a patient with TB.
• •Known or suspected HIV infection
• •Treatment with corticosteroids or other immunosuppressive therapy, including monoclonal antibodies against tumour necrosis factor-alpha (TNF-alpha) (e.g. infliximab, etanercept, adalimumab).
• •Born to a mother treated with bDMARDS (e.g. TNF-alpha blocking monoclonal antibodies) in the 3rd trimester;
• •Congenital cellular immunodeficiencies including specific deficiencies of the interferon gamma pathway;
• •Malignancies involving bone marrow or lymphoid systems;
• •Serious underlying illness including severe malnutrition;
• •Medically unstable;
• •Generalised septic skin disease and skin conditions such as eczema, dermatitis and psoriasis;
• •Significant febrile illness;
• •Mother immunosuppressed;
• •Family history of immunodeficiency;
• •Consanguineous parents;
• •Multiple births more than twins.